Published in Virology on November 10, 1998
Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol (2000) 6.47
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol (2005) 4.64
Viral late domains. J Virol (2002) 4.51
Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol (2003) 4.47
Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. J Cell Biol (2006) 4.33
Structural organization of authentic, mature HIV-1 virions and cores. EMBO J (2003) 4.32
Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A (2006) 4.14
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A (2002) 4.14
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A (2004) 3.90
Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol (2000) 3.77
The structural biology of HIV assembly. Curr Opin Struct Biol (2008) 3.71
The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol (2005) 3.63
Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J Virol (2000) 3.54
Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A (2006) 3.31
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol (2004) 3.22
Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J (2007) 3.17
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol (1999) 3.13
Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol (2004) 3.09
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol (2000) 2.85
Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol (2007) 2.82
Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J Virol (2001) 2.82
Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog (2007) 2.75
Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol (2003) 2.73
Directed egress of animal viruses promotes cell-to-cell spread. J Virol (2002) 2.72
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol (2002) 2.66
Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 2.64
Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol (2004) 2.51
ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A (2008) 2.48
A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol (2000) 2.47
Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J Virol (2000) 2.46
Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol (2004) 2.41
Organization of immature human immunodeficiency virus type 1. J Virol (2001) 2.34
Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J (1999) 2.33
Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog (2008) 2.32
The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release. J Virol (2003) 2.19
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates. J Virol (2000) 2.11
Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. J Virol (2007) 2.08
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J Virol (2000) 2.07
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol (2002) 1.96
Mapping and characterization of the N-terminal I domain of human immunodeficiency virus type 1 Pr55(Gag). J Virol (2000) 1.90
Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. Proc Natl Acad Sci U S A (2010) 1.89
Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J Virol (2003) 1.79
Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J (2004) 1.77
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol (2006) 1.70
A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol (2008) 1.70
Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol (2007) 1.69
A novel fluorescence resonance energy transfer assay demonstrates that the human immunodeficiency virus type 1 Pr55Gag I domain mediates Gag-Gag interactions. J Virol (2004) 1.68
Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. J Virol (2007) 1.66
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication. J Virol (2002) 1.60
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood (2008) 1.58
Late domain-dependent inhibition of equine infectious anemia virus budding. J Virol (2004) 1.57
Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol (2002) 1.55
Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol (2001) 1.55
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol (2005) 1.55
The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding. PLoS Pathog (2009) 1.55
Lipids and membrane microdomains in HIV-1 replication. Virus Res (2009) 1.51
The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation. J Virol (2000) 1.50
Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol (2002) 1.50
A myristoyl switch regulates membrane binding of HIV-1 Gag. Proc Natl Acad Sci U S A (2004) 1.48
Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol (2007) 1.46
Human immunodeficiency virus type 1 assembly and lipid rafts: Pr55(gag) associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100. J Virol (2003) 1.43
Inositol pyrophosphate mediated pyrophosphorylation of AP3B1 regulates HIV-1 Gag release. Proc Natl Acad Sci U S A (2009) 1.42
Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol (2004) 1.39
Cryo electron tomography of native HIV-1 budding sites. PLoS Pathog (2010) 1.39
Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog (2013) 1.35
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol (2006) 1.35
Late viral interference induced by transdominant Gag of an endogenous retrovirus. Proc Natl Acad Sci U S A (2004) 1.34
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol (2009) 1.33
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol (2008) 1.31
Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology (2006) 1.30
Flexibility in HIV-1 assembly subunits: solution structure of the monomeric C-terminal domain of the capsid protein. Biophys J (2007) 1.29
Element-specific localization of Drosophila retrotransposon Gag proteins occurs in both nucleus and cytoplasm. Proc Natl Acad Sci U S A (2002) 1.28
Redundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly. J Virol (2005) 1.27
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J Virol (1999) 1.26
Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells. Proc Natl Acad Sci U S A (2001) 1.26
Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol (2000) 1.25
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virol (2003) 1.24
Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection. J Virol (2001) 1.24
Specific interaction of a novel foamy virus Env leader protein with the N-terminal Gag domain. J Virol (2001) 1.24
The transdominant endogenous retrovirus enJS56A1 associates with and blocks intracellular trafficking of Jaagsiekte sheep retrovirus Gag. J Virol (2006) 1.23
RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes. J Virol (2002) 1.21
Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant. J Virol (2003) 1.21
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol (2005) 1.21
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
HIV-1 assembly in macrophages. Retrovirology (2010) 1.20
Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J Virol (2012) 1.20
HIV-1 assembly: viral glycoproteins segregate quantally to lipid rafts that associate individually with HIV-1 capsids and virions. Cell Host Microbe (2008) 1.20
Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J Virol (2007) 1.18
The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release. J Virol (2004) 1.18
New insights into HIV assembly and trafficking. Physiology (Bethesda) (2011) 1.18
Effects of mutations in the human immunodeficiency virus type 1 Gag gene on RNA packaging and recombination. J Virol (2006) 1.17
Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J Virol (2012) 1.17